ESG-401

N/A

Report date: 2025/01/10 14:24:16

Base Information

Drug NameESG-401
Drug Alias NameESG-401STI-3258OQY-3258
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SN-38 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionAnti-Trop-2DNA topoisomerase I inhibitors
TargetsTumor-associated calcium signal transducer 2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Escugen Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Escugen Biotechnology Co LtdQilu Pharmaceutical Co LtdTot Biopharm Co Ltd
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[8] 
Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A